Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern

Xiaoqi Yu, Dong Wei, Wenxin Xu, Chuanmiao Liu, Wentian Guo, Xinxin Li, Wei Tan, Leshan Liu, Xinxin Zhang (), Jieming Qu (), Zhitao Yang () and Erzhen Chen ()
Additional contact information
Xiaoqi Yu: Shanghai Jiao Tong University School of Medicine
Dong Wei: Shanghai Jiao Tong University School of Medicine
Wenxin Xu: Shanghai Jiao Tong University School of Medicine
Chuanmiao Liu: First Affiliated Hospital of Bengbu Medical College
Wentian Guo: Shanghai Jiao Tong University School of Medicine
Xinxin Li: Shanghai Jiao Tong University School of Medicine
Wei Tan: Shanghai Jiao Tong University School of Medicine
Leshan Liu: Shanghai Jiao Tong University School of Medicine
Xinxin Zhang: Shanghai Jiao Tong University School of Medicine
Jieming Qu: Shanghai Jiao Tong University School of Medicine
Zhitao Yang: Shanghai Jiao Tong University School of Medicine
Erzhen Chen: Shanghai Jiao Tong University School of Medicine

Nature Communications, 2022, vol. 13, issue 1, 1-10

Abstract: Abstract The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the generation of variants that may diminish host immune responses to vaccine formulations. Here we show a registered observational clinical trial (NCT04795414), we assess the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine BBIBP-CorV in a cohort of 1006 vaccine recipients. No serious adverse events are observed during the term of the study. Detectable virus-specific antibody is measured and determined to be neutralizing in 698/760 (91.84%) vaccine recipients on day 28 post second vaccine dose and in 220/581 (37.87%) vaccine recipients on day 180 post second vaccine dose, whereas vaccine-elicited sera show varying degrees of reduction in neutralization against a range of key SARS-CoV-2 variants, including variant Alpha, Beta, Gamma, Iota, and Delta. Our work show diminished neutralization potency against multiple variants in vaccine-elicited sera, which indicates the potential need for additional boost vaccinations.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-29477-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-29477-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-29477-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().